CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bafna Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bafna Pharmaceuticals Ltd
Bafna Towers, 299, Thambu Chetty street
Phone: +91 4442677555p:+91 4442677555 CHENNAI, 600001  India Ticker: BAFNAPHBAFNAPH
Business Summary
Bafna Pharmaceuticals Limited is an India-based company, which is engaged in the manufacture of drugs and medicines and selling a reputed brand namely RARICAP. The Company caters to both domestic and international market. It operates in generic pharmaceutical segment. The Company manufactures 336 licensed pharmaceutical formulations and have globally registered 78 of its products. It supplies its products to the United Kingdom, Europe, and Australian markets. The Company's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. The Company’s subsidiary is Bafna Lifestyles Remedies Limited.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Whole Time Director ShanmugamHemalatha 47 9/10/2020 9/10/2020
Chief Executive Officer Mahaveer C.Bafna 9/10/2020 9/10/2020
Chief Financial Officer MelagiriSridhar 5/27/2017 5/27/2017
3 additional Officers and Directors records available in full report.

Business Names
Business Name
532989
BAFNAPH
BAFNAPHARM

General Information
Number of Employees: 588 (As of 3/31/2023)
Outstanding Shares: 23,656,335 (As of 9/30/2023)
Shareholders: 7,227
Stock Exchange: NSE
Fax Number: +91 4442677599


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 15, 2024